Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report Intel FAQ API Sign In →
52 /100
HIGH RISK
Score updated Jul 28, 2026

EDSA — Edesa Biotech, Inc. Dilution Risk Tracker

Track EDSA dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track EDSA — Get alerts when the score changes →

As of July 28, 2026, Edesa Biotech, Inc. (EDSA) has a DilutionWatch DilutionScore of 52/100, rated HIGH dilution risk. Edesa Biotech, Inc. has a market capitalization of $64.20M, 8.89M shares outstanding, 30 institutional holders tracked. Key dilution vectors include 1.12M outstanding warrants, approximately 18 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
25
📊 Float Risk
55
⚠️ Warrant Exposure
50
🔄Convertible Debt

Dilution Forecast

☀️
Clear
No significant dilution signals
7%
📜 Warrant Exercise 15%
• Warrant overhang: 12.6% of shares outstanding
🔔 Track EDSA — Get forecast alerts →

Market Data

Market Cap$64.20M
Shares Outstanding8.89M
Float3.85M
Cash$10.50M
DebtN/A
Short InterestN/A

Institutional Holdings

QoQ: ↑ 7.9% shares (2026Q1 vs prior)
30 institutional holders · 3.30M shares
#1 PERCEPTIVE ADVISORS LLC 1.13M shares
#2 Velan Capital Investment Management LP 827.5K shares
#3 Rubric Capital Management LP 687.5K shares
+ 17 more holders Sign up free to view →

Short Interest

Short Interest282.9K
Days to Cover5.4
% of Float7.3%
FINRA data as of Jul 15, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2026-03-31
xbrl XBRL WARRANT 2026-03-31
Full SEC filing analysis available with free account

Recent News

No recent news

What This Means for EDSA Shareholders

Edesa Biotech, Inc. (EDSA) has a DilutionScore of 52/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 28, 2026, updated from SEC EDGAR data.

DilutionWatch tracks 1.1M outstanding warrants for EDSA. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window.

DilutionWatch tracks over 25 SEC filing types for EDSA in real-time, scanning EDGAR every 60 seconds. The DilutionWatch shows real-time score changes for EDSA alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.

Warrants Explained →

Understanding EDSA's Dilution Risk Factors

Primary Risk Drivers

The most significant dilution risks for Edesa Biotech stem from its Offering Ability and Cash Runway scores. Offering Ability is at a concerning level, indicating the company has active programs to raise capital through equity offerings, which inherently dilutes existing shareholders. The Cash Runway score of 25 reflects a moderate risk of needing additional funding soon, further increasing the likelihood of future equity issuance. These two factors together suggest that EDSA may be actively seeking capital and is not in a position to rely solely on retained earnings or internal cash generation.

Factors Currently Not a Concern

Several dilution-related factors remain at low risk levels. Convertible Note Risk is currently minimal, suggesting no immediate convertible debt obligations are likely to convert into equity. Float Risk also remains manageable, indicating that while the company has a public float, it is not excessively large or volatile. A change in either of these areas could elevate risk: an increase in outstanding convertible notes would raise the potential for dilution, and a significant rise in trading volume or market capitalization could signal increased interest that might lead to more issuance.

SEC Filings to Watch

Several filing types are critical to monitor. An S-3 registration statement signals an intent to offer securities on a continuous basis, potentially leading to frequent dilution. A 424B5 filing often accompanies equity offerings and indicates the company is preparing to issue new shares. An 8-K Item 1.01 report may signal new equity issuances or significant corporate actions that could impact share count. Additionally, a 10-Q filing can reveal changes in capital structure or cash position that might foreshadow future dilution events.

How Dilution Happens

Dilution occurs when existing shareholders' ownership percentage decreases due to new shares being issued. In EDSA’s case, the elevated Offering Ability score suggests ongoing equity programs, likely through registered offerings or private placements. The Cash Runway factor supports this by indicating a need for capital, which may lead to new share issuance. When these offerings occur, the total number of shares outstanding increases, reducing each existing shareholder's percentage ownership and potentially diminishing earnings per share.

What Would Make This Worse

The risk profile could deteriorate significantly if EDSA enters into multiple simultaneous equity programs or begins issuing convertible notes with low conversion prices. A drop in Cash Runway below 10 would signal an urgent need for capital, increasing the probability of immediate dilution. Additionally, if the company starts offering warrants or engages in reverse stock splits after a large issuance, it could compound dilution effects and negatively impact shareholder value.

Key Insight

While EDSA’s current cash runway is sufficient to avoid immediate liquidity issues, the elevated Offering Ability and Cash Runway scores suggest that future capital raises are likely, making ongoing monitoring of equity issuance critical for existing shareholders.

How to Monitor EDSA for Dilution Risk

What This Risk Level Means

For an operating company like Edesa Biotech, Inc., a high dilution risk profile signals that the firm is likely relying heavily on equity financing to fund operations. As a micro-cap entity, EDSA has limited access to traditional capital markets and must frequently issue new shares or securities to maintain liquidity. The elevated factors—offering ability, float risk, warrant exposure, and convertible note risk—indicate potential for significant share dilution in the near term. This level of risk is particularly concerning for small-cap companies where a single large issuance can drastically reduce existing shareholder value.

What Typically Happens Next

Companies at this profile often proceed with shelf registrations or ATM programs to raise capital quickly, especially if they are in early-stage operations. Warrant exercises and convertible note conversions may occur as part of routine financing rounds. In many cases, such companies will see a spike in new share issuance within 6–12 months post-filing, particularly when nearing cash runway limits. Monitoring these events is critical, as they can significantly impact ownership percentage for current investors.

Monitoring Playbook

To effectively track EDSA, use DilutionWatch to set up alerts for key financial filings and equity activity changes. Monitor SEC filings monthly for new offerings, warrant expirations, and convertible note conversions. Set thresholds at scores of 60/100 or higher for any dilution factor, as this may indicate a worsening risk profile. When these thresholds are hit, review the company’s recent capital structure updates and cash runway estimates. Additionally, check Shelf & ATM Monitor for upcoming filings that could signal future issuance events.

Early Warning Signals

Three key warning signs include: 1) A sudden increase in the number of warrants or convertible notes outstanding, 2) Filing a shelf registration statement, and 3) An upward trend in Offering Ability or Float Risk scores on DilutionWatch. These signals often precede major equity issuances that can dilute existing shareholders. Any change in these metrics should prompt immediate investigation into new capital raises or financial restructuring.

What a Positive Resolution Looks Like

A positive shift would occur if EDSA completes a significant capital raise, reduces outstanding warrants or convertible notes, or experiences a notable decrease in Offering Ability or Float Risk. Alternatively, if the company pays down debt or achieves a sustainable cash runway beyond 18 months, the overall dilution risk profile could improve. These changes would reflect stronger financial stability and reduced reliance on equity financing.

Watch For

Any filing related to new share issuance or warrant exercise within the next quarter, as these events can rapidly increase dilution risk.

Full SEC filing analysis available with free account  →
Track EDSA Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking EDSA — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for EDSA
EDSA FDA Catalyst Timeline & Biotech Grade — BiotechSignsEDSA Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.